Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years

Table 2

Clinical and pathological associations with pCR by univariate analysis. This table lists tumor characteristics (size, receptor expression, and histology), patient characteristics (age, BMI, and clinical LAD), and treatment characteristics (standard NACT versus carboplatin-containing NACT and dual HER2 blockade regimens) and their associations with pCR rates.

Characteristic	pCR = no	pCR = yes	Test statistic
	Mean (SD)	Mean (SD)		()
	Age	53.00 (12.8)	46.67 (13.2)	2.28 (0.51)
Initial tumor size (cm)	3.01 (2.0)	2.80 (1.8)	0.55 (0.59)
BMI	28.0 (7.9)	27.4 (6.1)	0.41 (0.37)
	(%)	(%)	()
Clinical LAD
(i) Yes	49 (63.6)	16 (57.1)	0.370 (0.545)
(ii) No	24 (36.4)	14 (42.9)
Hormone rec only
(i) Yes	29 (37.7)	4 (13.8)	6.00 (0.018)
(ii) No	54 (62.3)	26 (86.2)
HER2+
(i) Yes	25 (30.1)	18 (60.0)	8.57 (0.003)
(ii) No	58 (69.9)	12 (40.0)
TNBC
(i) Yes	29 (34.9)	8 (26.7)	0.34 (0.563)
(ii) No	54 (65.1)	22 (73.3)
Time period
(i) Before	49 (62.8)	8 (26.7)	11.36 (0.001)
(ii) After	29 (37.2)	22 (73.3)
Regimen
(i) Standard	58 (81.7)	15 (50)	10.99 (0.004)
(ii) Carboplatin-containing	3 (4.2)	5 (16.7)
(iii) Dual HER2 blockade	10 (14.1)	10 (33.3)

BMI: body mass index; HER2: human epidermal growth factor receptor 2; hormone rec only: hormone receptor only; LAD: lymphadenopathy; NACT: neoadjuvant chemotherapy; pCR: pathological complete response; TNBC: triple negative breast cancer.
Notes. ⁢; row data does not match column data in all cases.